Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the company’s growth. Doubling overall capacity, the laboratories enable the team’s accelerated expansion, and the development of new, innovative products.
The new facilities accommodate recent hires to Sphere Fluidics’ commercial and leadership team, as well as preparing for further recruitment by the end of the year. The first phase of building has opened 7,000 sq ft of space and has been purpose built with state-of-the-art equipment, including a demonstration lab to give customers the opportunity to see the company’s single cell analysis and monoclonality assurance systems at work. The second phase, due to be completed by the end of the 2023, will expand the company’s footprint further to around 30,000 sq ft.
Granta Park is one of the UK’s leading life-science research parks and a world-renowned centre of excellence.